Neurosurgical Oncology Ward 6

This ward is a comprehensive treatment ward for glioma-based supratentorial brain tumors, with more than 700 brain tumor surgeries completed every year from 2018-2022, including about 400 glioma surgeries, without surgical deaths and disability rates all significantly lower than international levels.

Neurosurgical Oncology Ward 6 specializes in:

1) Precise surgical resection of functional area and deep glioma: The team is the first in China to carry out multimodal intraoperative neurological function protection technology based on intraoperative real-time imaging and electrophysiological monitoring, which effectively protects essential functions such as motor, language, and spatial cognition of glioma patients and reduces post-operative complications while maximizing tumor removal. The treatment level of glioma of the thalamus, glioma of the insula, and glioma of the functional area are in the leading international position.

(2) Individualized comprehensive treatment of glioma and translational medicine research: The team is committed to individualized and standardized treatment of glioma based on multidimensional histological detection. In cooperation with the Department of Hematology and Oncology, the team is the first in China to carry out targeted treatment of patients with BRAF V600E mutation glioma with veronal. It is currently the only clinical unit in China capable of carrying out chemotherapy with PCV regimen for patients with 1p19q double deletion glioma, effectively prolonging the survival of patients with high-grade glioma. We also focus on the clinical therapeutic research of glioma, such as ADV-tk gene therapy for recurrent high-grade glioma, GP96 immunotherapy for incipient glioblastoma, seedling treatment for IDH1 mutated low-grade glioma, and fluorescence imaging-guided glioma resection surgery, etc. We have registered six international multicenter clinical studies.

(3) Surgical treatment of complex intracranial tumors: Through strict preoperative evaluation and multidisciplinary cooperation, we have completed surgical treatment of giant meningioma, posterior tri-compartmental tumor, and complex craniopharyngioma.

Treatment scope

1) Precision surgical treatment of glioma;

2)comprehensive treatment of malignant brain tumors under the guidance of genomics;

3) surgery and comprehensive treatment of brain metastases;

4) surgical treatment of meningioma, pituitary tumor, craniopharyngioma, and nerve sheath tumor;

Honors:

It has been awarded the title of excellent hospital group many times.

Leader:

Prof. Nan Ji: Chief physician, professor, doctoral supervisor, and current ward director. After graduating from Capital Medical University in 1994, he joined Beijing Tiantan Hospital Neurosurgery Department, specializing in the surgery and comprehensive treatment of intracranial tumors. He has performed more than 4,000 intracranial tumor surgeries. He is responsible for eight national and provincial projects on surgery, comprehensive glioma treatment, and medical Big Data. In the past five years, he has edited three books, published 22 papers in core journals with first and corresponding authors, 17 SCI-indexed papers, and hosted 3 international clinical research projects. He was awarded the Second Prize from the Ministry of Education in 2009 and one scientific research achievement from the Ministry of Education in 2007.

Experts:

Dr. Zhixian Gao: He specializes in the basic research and clinical work of brain tumors and specializes in the surgical treatment of large and deep intracranial tumors (thalamic tumors, posterior tri-compartmental tumors, saddle area tumors) and the individualized comprehensive therapy of glioma. He is currently a member of the Chinese Medical Association Neurosurgery Branch, the Chinese Health Care Association Neurosurgery Branch, a consultant of the Chinese Journal of Neuropsychiatric Diseases, and a reviewer of the Chinese Journal of Neurosurgery. In addition, he is currently undertaking one international cooperative project with the National Natural Science Foundation of China, and one project with the Beijing Natural Science Foundation of China. He is collaborating with the Mount Sinai School of Medicine to conduct post-operative neurosurgical brain cognition research.

Dr. Junsheng Chu: As a deputy chief physician, professor, and master's degree supervisor, he graduated from Beijing Neurosurgery Institute in 2004 under the supervision of Academician Zhongcheng Wang. 2016-2017 Postdoctoral work at the University of Washington Medical Center, U.S.A. Director of AO Spine International Organization Asia Pacific, Director of Beijing Medical Engineering Society, Member of World Neurosurgery Association, Member of Chinese Medical Association Neurosurgery Branch. He was selected as a member of the Beijing Science and Technology Rising Star Program in 2005. He has presided over and participated in many key National Natural Science Foundation of China projects and municipal science and technology projects. He has won the second prize in the Beijing Science and Technology Award and the third prize in the Ministry of Science and Technology Progress of the Ministry of Education. In recent years, he has published more than 20 papers in domestic and international journals and edited four books. He specializes in diagnosing and treating supratentorial tumors, skull base tumors, pediatric tumors, spinal cord tumors, traumatic brain injury, vascular disease, and functional neurosurgery and neurosurgical diseases.

Dr. Shuyu Hao: M.D., Chief physician, associate professor, master's degree supervisor, currently deputy director of the sixth ward of the Department of Neurosurgery of Beijing Tiantan Hospital. Dr. Hao completed his doctoral study in Beijing Neurosurgical Institute directed by Prof. Chungcheng Wang in 2009. He worked as visiting fellow in Neuro-oncology Branch in National Cancer Institute (Bethesda, Maryland, U.S.) in 2016. Now, Dr. Hao focus on the novel treatment methods in glioma and malignant meningioma，natural history research of meningioma, molecular genetic mechanism and tumor proteomics of recurrent meningioma, rare tumors of the nervous system.

Neurosurgical Oncology Ward 6This ward is a comprehensive treatment ward for glioma-based supratentorial brain tumors, with more than 700 brain tumor surgeries completed every year from 2018-2022, including about 400 glioma surgeries, without surgical deaths and disability rates all significantly lower than international levels. Neurosurgical Oncology Ward 6 specializes in: 1) Precise surgical res…